PRAME and cancer: Antigen-specific cancer immunotherapeutics typically induce less toxicity than cytotoxic agents and non-specific immunotherapeutic treatments targeting T-cell checkpoints.10, 11 We conservatively predefined DLT based on the pattern of PRAME expression in healthy tissue, notably on potential adrenal and renal AEs.